Imagion is a privately owned company based in Germany. Founded in 2000, it employs approximately 30 individuals and reported $3.3M in revenue as of 2023. The company operates as an authoring and encoding studio for VOD content, specializing in media managed services.
Pitt Street Research reported on Imagion's valuation, estimating it to be 75-80% below its target range of 12.3 to 14.9 cents per share, with potential upside depending on MagSense technology commercialisation. Imagion provided a business and MagSense HER2 Breast Cancer diagnostic imaging program update, anticipating a Phase 2 clinical trial to begin towards the end of 2025. The company began manufacturing the MagSense HER-2 imaging agent for a Phase 2 breast cancer trial planned for later this year. Additionally, Imagion is preparing an Investigational New Drug Application with the FDA and is collaborating with Siemens and Wayne State University on AI imaging protocol optimisation.
Imagion offers 4 products in the media tech industry. Imagion's product portfolio comprises of media managed services.
Subscribe for full access to Imagion's products in full detail
Imagion's revenues were less than $10M in 2023. Caretta Research has split Imagion's revenue into 4 different product categories, the largest of which is post production services. For full access to Imagion's revenue breakdown subscribe to Caretta Portal.
Subscribe for full access to Imagion's revenue in full detail
Subscribe for full access to Imagion's products in full detail 
